Frank M. Fischer
Known title: DirectorCIK: 0001297260
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Tenon Medical launches Symmetry+ 3D printed screw. Tenon Medical announced the full commercial launch of its Symmetry+ SI Joint Fusion 3D printed lateral screw following a successful alpha launch. This marks a key step in the company's product rollout, expanding its commercial footprint in the orthopedic market. The news highlights the company's focus on titanium 3D-printed solutions for spinal and joint fusion procedures.
Transaction History
| NPCE | ▲ Buy | Grant | 1,467 | $23K | 6/19/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 2,890 | $0 | 6/5/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 1,826 | $24K | 3/20/2026 | View on chart |
| NPCE | ▲ Buy | Grant | 1,431 | $24K | 12/19/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 2,389 | $24K | 9/19/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 2,281 | $24K | 6/21/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 1,975 | $24K | 3/21/2025 | View on chart |
| NPCE | ▲ Buy | Grant | 2,059 | $24K | 12/21/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 3,407 | $24K | 9/30/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 3,141 | $24K | 6/28/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 1,799 | $24K | 3/29/2024 | View on chart |
| NPCE | ▲ Buy | Grant | 2,303 | $24K | 12/29/2023 | View on chart |
| NPCE | ▲ Buy | Grant | 2,440 | $24K | 9/29/2023 | View on chart |
| NPCE | ▲ Buy | Grant | 4,469 | $20K | 6/30/2023 | View on chart |
| TNON | ▲ Buy | Option Exercise | 6,207 | $10K | 5/22/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating
Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.
Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating. Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.